-
Oct 2007
Disparity in holoprotein/apoprotein ratios of different standards
used for immunoquantification of hepatic cytochrome P450
enzymes.
Drug Metabolism & Disposition
35(10), 1733-1736, October 2007.
View abstract and full text options
-
Oct 2007
Prediction of intestinal first-pass drug metabolism.
Current Drug Metabolism
8(7), 676-684, October 2007.
View abstract and full text options
-
Jun 2007
Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition.
European Journal of Pharmaceutical Sciences
31(3-4), 232-241, July 2007.
View abstract and full text options
-
May 2007
Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.
European Journal of Pharmaceutical Sciences
32(1), 8-16, September 2007.
View abstract and full text options
-
Mar 2007
Misuse of the well-stirred model of hepatic drug clearance.
Drug Metabolism & Disposition
35(3), 501-502, March 2007.
View abstract and full text options
-
Feb 2007
Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA).
European Journal of Pharmaceutical Sciences
31(1), 53-61, May 2007.
View abstract and full text options
-
Jan 2007
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies - CYP2C9 and warfarin as an example.
British Journal of Clinical Pharmacology
64(1), 14-26, July 2007.
View abstract and full text options
-
Jan 2007
Simulation and prediction of in vivo metabolic drug clearance from in vitro data.
Nature Reviews Drug Discovery
6(2), 140-148, February 2007.
View abstract and full text options
-
Jan 2007
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Current Drug Metabolism
8(1), 33-45, January 2007.
View abstract and full text options
-
Jan 2007
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphisms on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.
Journal of Clinical Pharmacology
47(2), 175-186, February 2007.
View abstract and full text options